Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited · Author: FormBlends Editorial
Key Takeaways
- Kelly Osbourne confirmed gastric sleeve surgery (vertical sleeve gastrectomy) in 2018; this accounted for approximately 85 pounds of her weight loss
- Her public statements about Ozempic have been mixed; she has discussed the medication in personal terms in some interviews and emphasized surgery as the primary driver in others
- Patients combining bariatric surgery with GLP-1 medication is a real and increasingly common clinical pattern
- Her mother Sharon Osbourne separately confirmed Ozempic use in 2023; the two cases are sometimes conflated
- Coverage of Kelly Osbourne's statements requires careful sourcing because some quotes have been aggregated from podcasts and social-media commentary rather than formal interviews
Direct answer
Kelly Osbourne has confirmed gastric sleeve surgery as the primary driver of her transformation. Her public statements about Ozempic have been mixed across appearances. She has, in some interviews, described Ozempic as part of her broader weight-management approach alongside the surgical reset. She has not made a single definitive confirmation statement comparable to Oprah's or Tracy Morgan's, but her statements indicate the medication has been part of her management strategy at points. The honest summary requires both pieces (the surgery and the mixed Ozempic discussion) rather than a single yes/no.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- What Kelly Osbourne has actually said
- The gastric sleeve confirmation (2018-2022)
- The Ozempic discussion (2023-2024)
- What gastric sleeve plus Ozempic looks like clinically
- Distinguishing Kelly from Sharon Osbourne
- Post-pregnancy context
- The clinical case for combining surgery and medication
- The contrary view: how to read mixed celebrity statements
- Decision framework
- FAQ
- Sources
What Kelly Osbourne has actually said
Kelly Osbourne's public statements about her body and medication use span multiple years and platforms. The key data points:
2018. She underwent vertical sleeve gastrectomy. She did not publicly disclose at the time.
2020. On the Hollywood Raw podcast with Dax Holt and Adam Glyn, she discussed the surgery for the first time. She described it as "the easy part," emphasizing that the harder work was the mental and dietary follow-through.
2022. In interviews tied to her pregnancy with her son (with Sid Wilson of Slipknot), she discussed weight changes openly.
2023-2024. In various interviews and podcast appearances, she has discussed Ozempic in mixed terms. Some appearances emphasize that her surgery is the primary explanation; others discuss Ozempic in more personal terms as part of her broader weight-management approach. The exact framing varies across sources.
Coverage of her 2023-2024 statements has sometimes been aggregated and reframed by entertainment outlets. The cleanest individual statements are her direct podcast appearances rather than the headline-level coverage of them.
The gastric sleeve confirmation (2018-2022)
The gastric sleeve surgery is the most clearly documented element of Kelly Osbourne's transformation. Her own statements about it:
- The procedure was vertical sleeve gastrectomy (VSG), not gastric bypass or other variants
- She had the surgery in 2018
- She lost approximately 85 pounds in the post-surgical period
- She characterized the surgery as "a tool, not a cheat code" in her Hollywood Raw appearance
- She emphasized that dietary and emotional work continued after the procedure
Vertical sleeve gastrectomy is a well-studied bariatric procedure. Average weight loss in published series is approximately 25-30% of total body weight over 1-2 years. For someone of Osbourne's reported starting weight (in the 230-260 pound range based on prior public photos), 85 pounds is consistent with the upper range of typical VSG outcomes.
The surgery alone is a sufficient explanation for the magnitude of her early transformation. The Ozempic question, if applicable, would relate to maintenance and to addressing weight regain over time rather than the primary loss.
The Ozempic discussion (2023-2024)
In appearances after her son's birth and through 2023-2024, Osbourne has discussed Ozempic in mixed ways. The pattern across interviews:
Some statements appear to be personal discussion of the medication as part of her management strategy. Other statements emphasize the gastric sleeve as the primary driver and downplay the role of Ozempic.
What is reasonable to conclude:
- She has discussed Ozempic in personal terms in at least some appearances
- The medication appears to have been part of her broader weight-management approach at certain points
- She has not described herself as primarily reliant on the medication; the surgery remains the most-emphasized intervention
- The exact current status of her medication use is not clearly stated
The most accurate framing: "Kelly Osbourne has discussed Ozempic as part of her weight-management approach at points; she has primarily attributed her transformation to gastric sleeve surgery in 2018 and the ongoing dietary work afterward."
This is more nuanced than a simple confirmation or denial. It reflects the actual record of her statements rather than collapsing them into a single headline summary.
What gastric sleeve plus Ozempic looks like clinically
The combination of bariatric surgery plus GLP-1 medication is increasingly common in obesity medicine. The pattern:
- Initial weight loss following surgery is rapid (often 25-30% of body weight in the first 1-2 years)
- Many patients experience some weight regain in years 3-5 post-surgery
- GLP-1 medication can be added to address regain or to support continued loss
- The combination is supported by emerging clinical evidence; a 2024 study in Obesity Surgery (Lautenbach et al.) found semaglutide reduced regain by 4-7% of body weight in patients with post-bariatric weight rebound
This pattern is medically reasonable and increasingly common. If Kelly Osbourne has used Ozempic post-surgically, this is consistent with standard practice for patients in her situation.
Distinguishing Kelly from Sharon Osbourne
Kelly Osbourne and her mother Sharon Osbourne are sometimes conflated in coverage. The two cases are distinct:
| Feature | Kelly Osbourne | Sharon Osbourne |
|---|---|---|
| Confirmed Ozempic use | Mixed statements | Yes, in UK media 2023 |
| Surgical history | Gastric sleeve 2018 | No bariatric surgery confirmed |
| Approximate weight loss | ~85 lb (post-surgery) | ~30 lb (Ozempic) |
| Reason for stopping Ozempic | Status not clearly disclosed | "Lost too much weight" |
| Age at intervention | 33-37 | 70+ |
Sharon Osbourne's 2023 Ozempic confirmation in UK media was a clear, on-the-record disclosure. She named the medication, described the loss magnitude, and explained why she stopped. Kelly's statements are more layered and require careful sourcing.
Post-pregnancy context
Kelly Osbourne gave birth to her son Sidney with Sid Wilson in late 2022. Her body changes since then must be understood in the context of:
- Pregnancy weight gain and post-pregnancy retention dynamics
- Breastfeeding effects on appetite and metabolism
- The general post-pregnancy weight retention pattern (15-20% of women retain 10+ pounds at one year postpartum per ACOG)
- The complication of weight management after bariatric surgery during pregnancy
Her appearance in 2023-2024 shows continued slim presentation despite the post-pregnancy context. She has attributed this to dietary discipline, breastfeeding, and (in some accounts) medical support. The medical support reference is among the elements that has fueled Ozempic speculation in some coverage.
The clinical case for combining surgery and medication
The medical rationale for combining bariatric surgery and GLP-1 medication has grown since 2022:
- Long-term outcomes from sleeve gastrectomy show meaningful regain in 30-40% of patients by 5-10 years post-surgery
- GLP-1 medication addresses the underlying appetite and metabolic mechanisms that drive regain
- The combination produces better long-term weight maintenance than surgery alone
- Major obesity-medicine guidelines now acknowledge the combination as appropriate for patients with post-bariatric regain
If Kelly Osbourne is using Ozempic post-surgically, she is following a clinically sensible pattern. This is not a moral failing or a contradiction of her surgical commitment. It is current standard practice for many patients in her situation.
The contrary view: how to read mixed celebrity statements
The honest difficulty: Kelly Osbourne's statements do not yield a clean yes or no on Ozempic. Three interpretive frames:
Frame 1: She has confirmed use and the mixed statements reflect evolution.
In this reading, her earlier statements emphasized surgery because she was protective of her surgical identity. Her later statements increasingly acknowledge Ozempic because the cultural context has shifted toward disclosure. The "confirmation" is real but spread across appearances rather than concentrated in a single moment.
Frame 2: She has discussed Ozempic in general terms but not in personal terms.
In this reading, some quotes attributed to her have been reframed by outlets. She has discussed GLP-1 medications as a category in interviews about weight-loss culture, and aggregation has converted those discussions into apparent personal confirmation. The reality is that surgery remains the only clearly confirmed intervention.
Frame 3: She uses Ozempic but has not made it a focal point of her public identity.
In this reading, the medication is part of her management approach but she does not want it to define her transformation story. The surgery narrative is more emotionally meaningful to her, and Ozempic is mentioned only when directly asked.
The available evidence does not cleanly distinguish among these. The reasonable summary: she has discussed Ozempic in personal terms in some appearances, has emphasized surgery as the primary explanation in others, and has not made a single canonical confirmation statement.
Decision framework
If you are considering bariatric surgery:
- Vertical sleeve gastrectomy is well-established with documented average outcomes of 25-30% body weight loss
- Long-term follow-up shows some regain in many patients
- Combining surgery with GLP-1 medication is increasingly common and supported by emerging evidence
- Surgery is a major medical intervention requiring full pre- and post-operative care
If you are considering GLP-1 medication after bariatric surgery:
- This is supported by clinical practice for managing post-bariatric weight regain
- Discuss with your bariatric surgeon and obesity medicine specialist
- Dosing and titration may differ from primary GLP-1 use in non-surgical patients
If you are evaluating Kelly Osbourne's example specifically:
- Her surgery is clearly documented and is the primary explanation for her initial transformation
- Her Ozempic statements are mixed; do not assume a clean confirmation or denial
- The combination she may follow (surgery plus medication) is a real and clinically reasonable pattern
FAQ
Has Kelly Osbourne confirmed Ozempic use? Kelly Osbourne's public statements about Ozempic have been mixed across appearances. She has confirmed gastric sleeve surgery (vertical sleeve gastrectomy) in 2018. In some 2023-2024 interviews she has discussed Ozempic in personal terms; in others she has emphasized surgical reset as the primary driver. Her statements warrant careful reading rather than a single yes-or-no summary.
Did Kelly Osbourne have gastric sleeve surgery? Yes. Kelly Osbourne confirmed gastric sleeve surgery (vertical sleeve gastrectomy) in interviews in 2020-2022, attributing approximately 85 pounds of her transformation to the procedure plus subsequent dietary discipline. She had the surgery in 2018.
How much weight has Kelly Osbourne lost? She has publicly cited approximately 85 pounds of loss following her gastric sleeve surgery. Subsequent fluctuations have occurred, including post-pregnancy weight retention after the birth of her son in 2022 and described re-loss in 2023-2024.
What is gastric sleeve surgery and how does it compare to Ozempic? Gastric sleeve (vertical sleeve gastrectomy) is a surgical procedure that removes approximately 70-80% of the stomach, leaving a sleeve-shaped pouch. Average weight loss is 25-30% of body weight over 1-2 years. Ozempic is a weekly injection (GLP-1 receptor agonist) producing roughly 14.9% weight loss over 68 weeks per the STEP 1 trial. They are different categories of intervention with different risk profiles.
Can a person take Ozempic after gastric sleeve surgery? Yes, this is clinically common. Patients who have had bariatric surgery sometimes regain weight over time and may add GLP-1 medication for additional weight management. The combination is supported by emerging clinical evidence and is increasingly part of obesity-medicine practice.
Why are Kelly Osbourne's statements about Ozempic confusing? She has discussed the medication in some interviews and downplayed it in others. Her 2023-2024 statements appear in podcasts and social-media commentary rather than formal long-form interviews. Coverage has sometimes conflated her broader discussion of weight-loss medications with personal confirmation. Careful sourcing matters.
Did Kelly Osbourne lose weight after her pregnancy? She gave birth to her son with Sid Wilson in late 2022. She has discussed post-pregnancy weight changes openly. Her 2023-2024 appearances show continued slim presentation, which she has attributed to a combination of dietary discipline, breastfeeding, and (in some accounts) medical support.
What about Sharon Osbourne, her mother? Sharon Osbourne confirmed Ozempic use in UK media in 2023. She reported losing approximately 30 pounds and described stopping the medication because she lost too much weight. Kelly and Sharon's cases are sometimes conflated in coverage; they are separate.
What dose of Ozempic would someone like Kelly Osbourne typically use? If applicable post-bariatrically, doses are often kept lower than standard obesity-indication doses (0.25-0.5 mg weekly rather than progressing to 2.4 mg) because patients who have had VSG can experience compounded gastrointestinal effects at higher GLP-1 doses. Individual titration depends on the prescribing clinician.
Is it reasonable to use Ozempic for post-pregnancy weight retention? Yes, if FDA criteria are met (BMI 30+, or BMI 27+ with comorbidities). Most clinicians recommend waiting 4-6 weeks after weaning before starting GLP-1 therapy because the medications are not recommended during breastfeeding per FDA labeling.
Sources
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM. 2021. (STEP 1)
- Lautenbach A et al. Semaglutide for Weight Regain Management After Bariatric Surgery. Obesity Surgery. 2024.
- Bhasker AG et al. Vertical Sleeve Gastrectomy: Long-Term Outcomes. Obesity Reviews. 2022.
- American Society for Metabolic and Bariatric Surgery. Updated Position Statement on Pharmacotherapy After Bariatric Surgery. 2023.
- Hollywood Raw Podcast with Dax Holt and Adam Glyn. Episode with Kelly Osbourne, 2020.
- American College of Obstetricians and Gynecologists. Committee Opinion: Postpartum Weight Retention. 2021.
- FDA Drug Approvals Database. Wegovy and Ozempic prescribing information.
- UK media coverage of Sharon Osbourne Ozempic confirmation, 2023.
- American Association of Clinical Endocrinologists. Clinical Practice Guidelines for Obesity Management. 2022.
- Garvey WT et al. Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
- Mannan M et al. Postpartum Weight Retention and Long-Term Cardiometabolic Risk. Obesity Reviews. 2023.
- Pearl RL et al. Weight Bias and Stigma: Public Health Implications. Obesity. 2023.
Footer disclaimers
Platform Disclaimer. FormBlends operates as a connector between eligible patients, U.S.-licensed clinicians, and U.S.-based pharmacies. FormBlends is not a surgical provider and does not facilitate bariatric procedures. We do not prescribe or dispense medications directly; all clinical decisions are made by independent providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide formulations are not FDA-approved. They are produced by state-licensed 503A compounding pharmacies in response to individual prescriptions. They are not equivalent to brand Wegovy, Ozempic, or Zepbound.
Results Disclaimer. Bariatric surgery outcomes and medication outcomes both vary substantially. Combining surgery and medication does not guarantee outcomes; individual response depends on baseline weight, surgical outcome, medication adherence, dietary adherence, and many other factors.
Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly. Slipknot is a registered trademark of its associated rights holder. FormBlends is not affiliated with, endorsed by, or sponsored by Kelly Osbourne, Sharon Osbourne, Sid Wilson, Slipknot, Novo Nordisk, Eli Lilly, or any other party referenced in this article.